tbuckley/cabot-search huggingface dataset:
Somatic Mutations Implicated In Myeloid Malignancies Are Frequent In Idiopathic Aplastic Anaemia and Its Relevance To Disease Classification and Treatment- a Comprehensive Analysis Of 150 Patients
Authors: Jie Jiang, Austin G Kulasekararaj, Alexander E Smith, Azim M Mohamedali, Shreyans A Gandhi, Barbara Czepulkowski, Judith Marsh, Ghulam J. Mufti
Journal: Blood (2013)
Relapse Prediction in AML Patients in Complete Remission Using WT1 as a Molecular Marker: Development of a Mathematical Model To Predict Time from Molecular to Clinical Relapse and Define Optimal Sampling Intervals.
Authors: Hans B. Ommen, Charlotte G. Nyvold, Karin Brændstrup, Bodil L. Andersen, Ingrid B. Ommen, Henrik Hasle, Peter Hokland, Mette Ostergaard
Journal: Blood (2007)
Bidirectional neuron-glioma interactions: effects of glioma cells on synaptic activity and its impact on tumor growth
Authors: Elena Tantillo, Eleonora Vannini, Chiara Cerri, Chiara Maria Mazzanti, Mario Costa, Matteo Caleo
Journal: Neuro-Oncology (2019)

Abstract Gliomas grow in a neuronal environment, but little is known on the functional changes in peritumoral neurons during tumor development. Moreover, investigations on the role of neural activity in glioma progression have yielded contradictory results. Here, we monitored longitudinal changes in network activity by recording visual evoked potentials (VEP) and local field potentials (LFP) after transplant of GL261 glioma cells in mouse visual cortex. We detected a progressive deterioration of VEP amplitudes in glioma-bearing mice, accompanied by an increase in slow network oscillations. At the cellular level, the analysis of microdissected peritumoral neurons showed alterations in both pre- and post-synaptic markers. To investigate whether glioma-driven alterations in synaptic function may impact on tumor growth, we manipulated levels of afferent cortical activity in glioma-bearing mice. Specifically, we tested blockade of synaptic activity via botulinum neurotoxin A (BoNT/A), visual deprivation (dark rearing, DR) and visual stimulation (VS). Replicating cells were quantified via immunostaining for BrdU and Ki67. We found that manipulation of cortical activity bidirectionally regulated glioma proliferation. Silencing of cortical synapses with BoNT/A and DR increased tumor proliferation while daily VS had the opposite effect. These findings demonstrate reduced responsiveness of peritumoral neurons which may in turn stimulate tumor cell proliferation, thus triggering a vicious loop that exacerbates glioma progression. Physiological stimulation of neural activity appears to restrain glioma proliferation so it could be implemented in the clinical setting as an adjuvant therapy.
Day +30 and Day +100 CD33 Chimerisms Predict Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelofibrosis
Authors: Tania Jain, M'hamed Temkit, Daniel K. Partain, Mrinal M Patnaik, James L. Slack, Nandita Khera, William J. Hogan, Vivek Roy, Pierre Noel, Jose F Leis, Lisa Sproat, Veena DS Fauble, Ruben A. Mesa, Jeanne Palmer
Journal: Blood (2016)
Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti-Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Authors: Matthew S. Davids, John M. Pagel, Brad S. Kahl, William G. Wierda, Thomas P. Miller, John F. Gerecitano, Thomas J. Kipps, Mary-Ann Anderson, David C.S. Huang, Nikita K. Rudersdorf, Lori A. Gressick, Nicholas P. Montalvo, Ccrp, Jianning Yang, Todd A. Busman, Martin Dunbar, Drph, Elisa Cerri, Sari H. Enschede, Rod A. Humerickhouse, Andrew W. Roberts
Journal: Blood (2013)
Polymorphisms in the Multiple Drug Resistance Protein 1 and in P-Glycoprotein 1 Are Associated with Time to Event Outcomes in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Bortezomib and Pegylated Liposomal Doxorubicin.
Authors: Gabriele Buda, Deborah Ricci, Nadine Cohen, Reyna Favis, C. Chris Huang, Wayne Rackoff, Sen H. Zhuang, Jean Luc Harrouseau, Pieter Sonneveld, Joan Blade, Robert Z. Orlowski
Journal: Blood (2009)
Recipient Epstein Barr Virus (EBV) Seropositivity with IgG Antibodies Against Early Antigens (EA) Could Be a Predictive Marker for the Early Onset of Post Transplant Lymphoproliferative Disorders (PTLDs) after Allogeneic Non T Depleted Stem Cell Transplantation.
Authors: Felix Agbalika, Jerome Larghero, Dominique Marais, Helene Esperou, Gerard Socie, Marc Benbunan, Eliane Gluckman, Jean Pierre Marolleau
Journal: Blood (2004)
Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia Relapsing after Allogeneic Stem Cell Transplantation
Authors: Jessica I Hoell, Sebastian Ginzel, Cornelia Eckert, Michael Gombert, Ute Fischer, Martin Stanulla, Martin Schrappe, Udo zur Stadt, Peter Bader, Brigitte Strahm, Julia Alten, Anja Moericke, Gabriele Escherich, Arend Stackelberg, Christina Peters, Arndt Borkhardt, Roland Meisel
Journal: Blood (2016)
Population Pharmacokinetics of Erwinia Asparaginase in Pediatric ALL Patients
Authors: Sebastiaan D.T. Sassen, Ron A.A. Mathôt, Rob Pieters, Valerie de Haas, Gertjan JL Kaspers, Cor van den Bos, Wim JE Tissing, Maroeska D.W.M. te Loo, Marc B Bierings, Wouter J.W. Kollen, Christian M. Zwaan, Inge M. van der Sluis
Journal: Blood (2015)
Synergistic Action of the Human Inhibitory KIR Antibody IPH2102, and the Human CD38 Antibody Daratumumab to Enhance the Lysis of Primary Multiple Myeloma (MM) Cells in the Bone Marrow Mononuclear Cells (MNCs) From Myeloma Patients
Authors: Inger S. Nijhof, Michel de Weers, Pascale Andre, Berris van Kessel, Henk M. Lokhorst, Paul W.H.I. Parren, Yannis Morel, Tuna Mutis
Journal: Blood (2011)
TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision
Authors: Zeyu Chen, Zhicheng Ji, Shin Foong Ngiow, Sasikanth Manne, Zhangying Cai, Alexander C. Huang, John Johnson, Ryan P. Staupe, Bertram Bengsch, Caiyue Xu, Sixiang Yu, Makoto Kurachi, Ramin S. Herati, Laura A. Vella, Amy E. Baxter, Jennifer E. Wu, Omar Khan, Jean-Christophe Beltra, Josephine R. Giles, Erietta Stelekati, Laura M. McLane, Chi Wai Lau, Xiaolu Yang, Shelley L. Berger, Golnaz Vahedi, Hongkai Ji, E. John Wherry
Journal: Immunity (2019)
Not All Plaque Erosions Are Equal
Authors: Jiannan Dai, Chao Fang, Shaotao Zhang, Jingbo Hou, Lei Xing, Lulu Li, Yini Wang, Jifei Wang, Yidan Wang, Yingfeng Tu, Xiling Zhang, Huimin Liu, Maoen Xu, Xuefeng Ren, Lijia Ma, Huai Yu, Guo Wei, Shaosong Zhang, Gary S. Mintz, Bo Yu
Journal: JACC. Cardiovascular imaging (2019)
Anti-donor MHC Class II Alloantibody Induces Glomerular Injury in Mouse Renal Allografts Subjected to Prolonged Cold Ischemia
Authors: Victoria Gorbacheva, Ran Fan, Ashley Beavers, Robert L. Fairchild, William M. Baldwin, Anna Valujskikh
Journal: Journal of the American Society of Nephrology (2019)

Significance Statement Prolonged cold-ischemia storage of donor organs is a major risk factor for acute and chronic graft injury, but the immunologic mechanisms underlying deleterious effects of cold-ischemia time and subsequent ischemia-reperfusion injury are poorly defined. In a mouse model of allogeneic kidney transplantation, the authors found that subjecting donor kidneys to prolonged cold ischemia enhanced early humoral and cellular anti-donor immune responses. In particular, recipients generated donor-specific antibodies against MHC class II (but not class I) antigens and exhibited extensive transplant glomerulopathy. The results indicate that antibodies against donor MHC class II antigens are critical mediators of glomerular injury caused by prolonged cold ischemia. Establishing mechanistic links between cold-ischemia storage and late transplant tissue injury may guide future therapies to ameliorate manifestations of chronic kidney allograft rejection. Background The mechanisms underlying the effects of prolonged cold-ischemia storage on kidney allografts are poorly understood. Methods To investigate effects of cold ischemia on donor-reactive immune responses and graft pathology, we used a mouse kidney transplantation model that subjected MHC-mismatched BALB/c kidney allografts to cold-ischemia storage for 0.5 or 6 hours before transplant into C57BL/6 mice. Results At day 14 post-transplant, recipients of allografts subjected to 6 versus 0.5 hours of cold-ischemia storage had increased levels of anti–MHC class II (but not class I) donor-specific antibodies, increased donor-reactive T cells, and a significantly higher proportion of transplant glomeruli infiltrated with macrophages. By day 60 post-transplant, allografts with a 6 hour cold-ischemia time developed extensive glomerular injury compared with moderate pathology in allografts with 0.5 hour of cold-ischemia time. Pathology was associated with increased serum levels of anti–class 2 but not anti–class 1 donor-specific antibodies. Recipient B cell depletion abrogated early macrophage recruitment, suggesting augmented donor-specific antibodies, rather than T cells, increase glomerular pathology after prolonged cold ischemia. Lymphocyte sequestration with sphingosine-1-phosphate receptor 1 antagonist FTY720 specifically inhibited anti–MHC class II antibody production and abrogated macrophage infiltration into glomeruli. Adoptive transfer of sera containing anti-donor MHC class II antibodies or mAbs against donor MHC class II restored early glomerular macrophage infiltration in FTY720-treated recipients. Conclusions Post-transplant inflammation augments generation of donor-specific antibodies against MHC class II antigens. Resulting MHC class II–reactive donor-specific antibodies are essential mediators of kidney allograft glomerular injury caused by prolonged cold ischemia.
Epinephrine-Induced Sickle Red Cell Adhesion and Vaso-Occlusion In Vivo Is Inhibited by the β-Adrenoceptor Blocker Propranolol.
Authors: Rahima Zennadi, Benjamin J. Moeller, Erin J. Whalen, Mark W. Dewhirst, Marilyn J. Telen
Journal: Blood (2004)
FDG-PET Scan Guided Consolidative Radiation Therapy Optimizes Outcome In Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma (DLBCL) with Residual Abnormalities on CT Scan Following R-CHOP
Authors: Laurie H. Sehn, Paul Hoskins, Richard Klasa, Tamara Shenkier, Randy D. Gascoyne, Francois Benard, Don Wilson, James Morris, Tom Pickles, Joseph M. Connors, Kerry J. Savage
Journal: Blood (2010)
Real-world experience with Temozolomide &amp; Sativex in patients with recurrent High Grade Gliomas
Authors: Lillie Shahabi, Kerlann Le Calvez, Seema Dadhania, Catherine Blake, James Wang, Manasi Ingle, Giulio Anichini, David Peterson, Dipankar Nandi, Sophie Camp, Waqar Saleem, Alison Falconer, Kevin O’Neill, Matt Williams
Journal: Neuro-Oncology (2019)

Abstract Background Glioblastoma (GBM) is the most common malignant brain tumour in adults with a median survival from progression of 8 months. A recent phase 1 study of temozolomide (TMZ) and 1:1 CBD:THC (Sativex) offers evidence of efficacy in patients with recurrent GBM (NCT01812603). Methods All patients receiving TMZ &amp; Sativex (75mg/m2 daily d1 – 21 q28; Sativex continuously) for relapsed GBM or grade 3 astrocytoma at our centre were identified. Patient, tumor and treatment characteristics were recorded, and response based on sequential MRI scans using modified RANO criteria assessed. Results 13 patients were treated over 18 months. The median age was 56; 69% were male. All had received initial chemo-radiotherapy (12 patients: 60 or 59.4Gy/30–33#; 1 patient: 45Gy/15#). 6 patients underwent reresection at recurrence. 4 patients were treated at first progression, 7 at second progression, and 2 at third or later progression. The median number of cycles of TMZ and sativex was 2. The combination treatment was tolerated well by all patients treated, with no Grade 3 or 4 toxicities, the only complaints being of discomfort in mouth after spray and ‘spaced out feeling’. Patients stopped treatment due to evidence of progressive disease on sequential MRI sign or physical deterioration. Median Overall Survival (OS) from initiation was 5.9 months (177 days); Progression Free Surival (PFS) at 3 months was 50%. Conclusion These results highlight some discrepancies in OS in comparison to the previous trial (NCT01812603), but our patients were treated at second/ third recurrence. We agree that the combination is well tolerated.
The Single-Agent Bcl-2 Inhibitor ABT-199 (GDC-0199) In Patients With Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Responses Observed In All Mantle Cell Lymphoma (MCL) Patients
Authors: Matthew S. Davids, John F. Seymour, John F. Gerecitano, Brad S. Kahl, John M. Pagel, William G. Wierda, Mary-Ann Anderson, Nikita K. Rudersdorf, Lori A. Gressick, Nicholas P. Montalvo, Jianning Yang, Todd A. Busman, Martin Dunbar, Elisa Cerri, Sari H. Enschede, Rod A. Humerickhouse, Andrew W. Roberts
Journal: Blood (2013)
RAS/RAF Pathway Mutations Define a Distinct Subset of Chronic Lymphocytic Leukemia
Authors: Rashmi Kanagal-Shamanna, Raja Luthra, Madan Luthra, Xinyan Lu, Mark Routbort, Nitin Jain, Michael Keating, L Jeffrey Medeiros, William Wierda, Keyur P. Patel
Journal: Blood (2015)
The Selective Protein Kinase CB Inhibitor, Enzastaurin, Induces In Vitro and In Vivo Antitumor Activity in Waldenstrom’s Macroglobulinemia.
Authors: Anne-Sophie Moreau, Xiaoying Jia, Garrett O’Sullivan, Xavier Leleu, Klaus Podar, John Daley, Suzan Lalo, Evdoxia Hatjiharisi, Hai Ngo, Mark Raab, Jean-Claude D’Halluin, Thierry Facon, Teru Hideshima, Steven Treon, Kenneth Anderson, Irene Ghobrial
Journal: Blood (2006)
Alpelisib (ALP)+fulvestrant (FUL) in patients from Japan with advanced breast cancer: Subgroup analysis of SOLAR-1 trial
Authors: Hiroji Iwata, Toshinari Yamashita, Kenichi Inoue, Masato Takahashi, Norikazu Masuda, Teruo Yamauchi, Yutaka Yamamoto, Toshimi Takano, Naoki Niikura, Takahiro Nakayama, Seiki Takashima, Koji Matsumoto, Yasuaki Sagara, Takaaki Fujii, Toru Hattori, Risa Sekiguchi, Celine Wilke
Journal: Annals of Oncology (2019)
The Incidence and the Risk Factors of Bowel Perforation Due to Chemotherapy in Gastrointestinal Diffuse Large B Cell Lymphoma
Authors: Takuro Matsumoto, Yuhei Shibata, Nobuhiko Nakamura, Hiroshi Nakamura, Soranobu Ninomiya, Junichi Kitagawa, Yasuhito Nannya, Masahito Shimizu, Takeshi Hara, Hisashi Tsurumi
Journal: Blood (2015)
Targeting Aberrant Ncam (neural cell adhesion molecule; CD56) Expression in Acute Myeloid Leukemia
Authors: Daniel Sasca, Andrea Schueler, Jakub Szybinski, Oliver Kriege, Kerstin Kunz, Eva Marie Fehr, Patricia Haehnel, Wolf Henning Gebhardt, Gerge Reid, Matthias Theobald, Lars Bullinger, Thomas Kindler
Journal: Blood (2015)
Whole Exome Sequencing Shows a Paucity Of Somatic Gene Mutations In Pediatric Idiopathic Bone Marrow Failure Syndrome
Authors: Atsushi Narita, Hideki Muramatsu, Kenichi Yoshida, Yusuke Okuno, Asahito Hama, Xinan Wang, Yinyan Xu, Nozomu Kawashima, Hirotoshi Sakaguchi, Sayoko Doisaki, Yoshiyuki Takahashi, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Satoru Miyano, Seishi Ogawa, Seiji Kojima
Journal: Blood (2013)
In-Vitro and in-Vivo Evaluation of the Orally Active Proteasome Inhibitor MLN9708 in Hematological Models of Human Cancer.
Authors: Erik Kupperman, Edmund Lee, Yueying Cao, Bret Bannerman, Michael Fitzgerald, Allison J Berger, Jie Yu, Julie Zhang, Paul Hales, Frank Bruzzese, Jane Liu, Jonathan Blank, Khristofer Garcia, Christopher Tsu, Larry Dick, Paul Fleming, Li Yu, Mark G Manfredi, Mark Rolfe, Joseph Bolen
Journal: Blood (2009)
Survival and Prognosis in Patients with First-Line Imatinib Treatment Under Particular Consideration of Death Due to Chronic Myeloid Leukemia
Authors: Markus Pfirrmann, Susanne Saussele, Michele Baccarani, Joelle Guilhot, Francisco Cervantes, Gert J Ossenkoppele, Doris Lindoerfer, Verena S Hoffmann, Fausto Castagnetti, Rüdiger Hehlmann, Bengt Simonsson
Journal: Blood (2014)
Early Allogeneic Hematopoietic Cell Transplantation during Induction Chemotherapy in High-Risk Acute Myeloid Leukemia.
Authors: Gerhard Ehninger, Uwe Platzbecker, Christian Thiede, Thomas Illmer, Ulrich S. Schuler, Markus A. Schaich, Martin Bornhaeuser
Journal: Blood (2004)
A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Authors: Daniel A. Pollyea, Steven Coutre, Lia Gore, Nichole Adler, Pamela Harris, Mitch A. Phelps, Amy J. Johnson, YongHua Ling, Hao Li, Jonathan A Gutman, John C. Byrd
Journal: Blood (2014)
Is There Still a Place for Total Body Irradiation (TBI) In the Conditioning Regimen of Autologous Stem Cell Transplantation In Mantle Cell Lymphoma ?: a Retrospective Study From the Lymphoma Working Party of the EBMT
Authors: Marie T Rubio, Ariane Boumendil, Jian Jian Luan, Carmen Canals, Francois Lefrère, Michel Attal, Augustin Ferrant, Agnès Buzyn, Bernard Rio, Anton Schattenberg, Juan Carlos Vallejo Llamas, Herve Tilly, Pierre Biron, Noel-Jean Milpied, Didier Blaise, Jean-Pierre Jouet, Charles Crawley, Peter Dreger, Anna Sureda, Olivier Hermine
Journal: Blood (2010)
The Collagen-Prolyl Hydroxylases promote proliferation and invasion in GBM
Authors: Elena Castellano, Aithne Atkinson, Kevin O’Neill, Nelofer Syed
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma Multiforme (GBM) is the most aggressive form of brain tumour, with a median survival time of just 14 months. Current standard therapy includes surgical excision, followed by chemotherapy and radiotherapy, however complete surgical excision is not usually possible due to the diffuse and infiltrative nature of the disease. To combat this, therapies inhibiting the invasion of leader migratory cells are an attractive area of research. The collagen prolyl-4 hydroxylases (C-P4Hs) are a family of proteins which catalyse the hydroxylation of proline residues on pre-pro-collagen, leading to the formation of the stable triple-helical structure of functional collagen. Collagen is a highly abundant protein, and important in several oncogenic cellular processes including proliferation, invasion and migration. We hypothesis that by inhibiting the C-P4Hs, the pro-tumorigenic effect of collagen will be inhibited in GBM. To explore this, we treated cells with ethyl 3,4-dihydroxybenzoate (EDHB) (a C-P4H inhibitor) and observed the resultant effect in GBM cells lines and primary cells through proliferation assays and 3D tumour spheroid invasion assays. Our results indicate that the addition of EDHB significantly reduces proliferation and invasion in both cell lines and primary GBM samples. Furthermore, we show that the C-P4Hs are upregulated in hypoxic conditions, which are commonly found in the clinical tumour microenvironment. Our study reveals that the C-P4H proteins may be an attractive therapeutic target to reduce invasion and proliferation and may be especially attractive as adjuvants with a cytotoxic agent such as temozolomide.
Allogeneic Stem Cell Transplantation (Allo-SCT) for De Novo Ph+ Acute Myeloid Leukemia: A Study from the French Society of Bone Marrow Transplantation and Cell Therapies
Authors: Sylvain P Chantepie, Mauricette Michallet, Didier Blaise, Sébastien Maury, Eric Deconinck, Reza Tabrizi, Nathalie Contentin, Mohamad Mohty, Stephanie Nguyen, Bruno Lioure, Nicole Raus, Regis Peffault de Latour, Ibrahim Yakoub-Agha, Oumedaly Reman
Journal: Blood (2014)
Gait Speed Reveals Clues to Lifelong Health
Authors: Stephanie Studenski
Journal: JAMA Network Open (2019)

Line Jee Hartmann Rasmussen, PhD; Avshalom Caspi, PhD; Antony Ambler, MSc; Jonathan M. Broadbent, PhD; Harvey J. Cohen, MD; Tracy d'Arbeloff, BA; Maxwell Elliott, BS; Robert J. Hancox, MD; HonaLee Harrington, BA; Sean Hogan, BA; Renate Houts, PhD; David Ireland, PhD; Annchen R. Knodt, MSc; Kim Meredith-Jones, PhD; Miriam C. Morey, PhD; Lynda Morrison, BSc; Richie Poulton, PhD; Sandhya Ramrakha, PhD; Leah Richmond-Rakerd, PhD; Maria L. Sison, BS; Kate Sneddon, PhD; W. Murray Thomson, PhD; Ahmad R. Hariri, PhD; Terrie E. Moffitt, PhD
Molecular Mechanisms of the mTOR Inhibitor Temsirolimus (CCI-779) Antiproliferative Effects in Mantle Cell Lymphoma: Induction of Cell Cycle Arrest, Autophagy, and Synergy with Vorinostat (SAHA).
Authors: Victor Y. Yazbeck, Georgios V. Georgakis, Yang Li, Eiji Iwado, Seiji Kondo, Anas Younes
Journal: Blood (2006)
The RNA Editase ADAR1 Promotes Malignant Progenitor Reprogramming in Chronic Myeloid Leukemia.
Authors: Qingfei Jiang, Leslie Crews-Robertson, Christian L Barrett, Hyn-June Chun, Angela C. Court-Recart, Daniel J Goff, Mark D. Minden, Anil Sadarangani, Jessica Rusert, Kim-Hien Dao, Sheldon R Morris, Lawrence S. B. Goldstein, Marco A. Marra, Kelly A Frazer, Catriona Jamieson
Journal: Blood (2012)
A New Prognostic Disease Specific Model To Predict Survival after Intensive Antileukemic Treatment for Young Patients with Poor-Risk MDS and AML: Results of the CRIANT and AML-10 Studies Conducted by the EORTC/GIMEMA/SAKK/HOVON/EBMT Groups.
Authors: M. Oosterveld, S. Suciu, P. Muus, M. Delforge, A. Belhabri, C. Aul, D. Selleslag, A. Ferrant, J.-P. Marie, S. Amadori, U. Jehn, U. Hess, R. Willemze, E. Hellstrom-Lindberg, M. Vignetti, B. Labar, F. Mandelli, T. De Witte
Journal: Blood (2004)
Development of a Clinically Relevant in Vitro Drug Screening Platform for Chemo-Refractory AML Patients
Authors: Stephen Sze Yuen Lam, Chae Yin Cher, Nelson Ka Lam Ng, Eric SK Ho, Cheuk Him Man, Howard CH Chow, Connie J Eaves, Alice MS Cheung, Anskar Y.H. Leung
Journal: Blood (2014)
A Prospective Randomized Trial of Oral Melphalan, Prednisone, Thalidomide (MPT) vs Oral Melphalan, Prednisone (MP): An Interim Analysis.
Authors: Antonio Palumbo, Alessandra Bertola, Pellegrino Musto, Tommaso Caravita, Vincenzo Callea, Clotilde Cangialosi, Anna Marina Liberati, Pasquale Niscola, Lucio Catalano, Mariella Grasso, Vito Michele Lauta, Maria Concetta Petti, Sergio Morandi, Monica Galli, Sara Bringhen, Federica Cavallo, Patrizia Falco, Mario Boccadoro
Journal: Blood (2004)
JMJD3 Plays Essential Roles in the Maintenance of Hematopoietic Stem Cells and Leukemic Stem Cells through the Regulation of p16INK4a
Authors: Yuichiro Nakata, Norimasa Yamasaki, Takeshi Ueda, Kenichiro Ikeda, Akiko Nagamachi, Toshiya Inaba, Hiroaki Honda
Journal: Blood (2016)
Increasing Functional Avidity of T Cell Receptor (TCR)-Redirected T Cells by Removing Defined N-Glycoslyation Sites in the Constant Domain of Introduced TCR Chains.
Authors: Juergen Kuball, Beate Hauptrock, Matthias Wolfl, Ralf Holger Voss, Roland Strong, Matthias Theobald, Phil Greenberg
Journal: Blood (2007)
Phase II Study of Infusional Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma
Authors: Nikoletta Lendvai, Heather Landau, Alexander Lesokhin, Ioanna Tsakos, Guenther Koehne, David Chung, Sean Devlin, Hani Hassoun, Sergio A Giralt
Journal: Blood (2012)
Microparticles Derived from Platelets (PMP), Endothelia (EMP), and Leukocytes (LMP) Exhibit Distinctive Hemostatic and Inflammatory Activities.
Authors: Wenche Jy, Joaquin J. Jimenez, Lawrence L. Horstman, Lucia M. Mauro, Carlos Bidot, Miriam Yaniz, Martha Gonzalez, Eugene R. Ahn, Carlos J. Bidot, Yeon S. Ahn
Journal: Blood (2005)
The efficacy and safety of FOLFIRI+BEV/mXELIRI+BEV by UGT1A1 polymorphisms in metastatic colorectal cancer AXEPT trial
Authors: Hiroshi Matsuoka, Yoshinori Kagawa, Mitsuyoshi Ota, Akitaka Makiyama, Kohei Akiyoshi, Tadamichi Denda, Chu Matsuda, Yasuhide Yamada, Satoshi Morita, Junichi Sakamoto, Kei Muro, Masato Nakamura, Masahito Kotaka, Tmohiro Nishina, Taichi Yabuno, Takanori Matsui, Satoru Iwasa, Tae Won Kim, Rui-Hua Xu, Young Suk Park
Journal: Annals of Oncology (2019)
Integrated Molecular Analysis of Myelodysplastic Syndromes Using Whole Genome Sequencing
Authors: Yasuito Nannya, Yoshida Kenichi, Keisuke Kataoka, Yasunobu Nagata, Tetsuichi Yoshizato, Tomoki Naoe, Hitoshi Kiyoi, Shigeru Chiba, Norio Asou, Yasushi Miyazaki, Hiroko Tanaka, Kenichi Chiba, Yuichi Shiraishi, Satoru Miyano, Seishi Ogawa
Journal: Blood (2016)